Glaxo Avandia Sales Appear To Be Vanishing (GSK)
GlaxoSmithKline’s (NYSE:GSK) Avandia sales might not just weak after the reports of cardiovascular risks were reported. If this research is accurate, the sales might be on the path to vanishing. We have…